Older adults with major depressive disorder (MDD) demonstrate distinct and riskier driving behaviors than those withou ...

Nelivaptan (NB-415, SSR-149415) is under development for the treatment of depression including major depressive disorder (MDD). The drug candidate targets vasopressin receptor 1B ( (V1bR). It is ...

The changing landscape of health care during COVID-19 placed focus on increasing accessibility to mental health resources other than the emergency department (ED), with potential savings of over $ ...

Researchers from Washington University found a common condition could make you more of a liability on the road as you age.

Major depressive disorder (MDD) is a chronic and recurrent mental condition leading to huge impacts on direct and indirect personal and public medical costs. To overcome such a serious mental ...

White matter alterations within the brain are associated with cognitive impairment among individuals with and without major ...

There is limited published data at higher doses and none in the treatment of Major Depressive Disorder (MDD). Methods This open-label, pilot study was designed to investigate the efficacy ...

In this longitudinal cohort study of older drivers, adults with major depressive disorder demonstrated distinct and riskier driving ...

Neumora Therapeutics to release phase 3 data on Navacaprant for MDD treatment in 2024. Check out NMRA's catalysts that might ...

Long-Acting Injectable Program is under clinical development by Intra-Cellular Therapies and currently in Phase I for Schizoaffective Disorder.

Here’s a look at the best and worst states in each of our four data categories: mental health provider ratio, percentage of ...

The following is a summary of “Service coverage for major depressive disorder: estimated rates of minimally adequate ...